# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs...
Bristol Myers Squibb gains access to Scenic's Cell-Seq technology platform to unlock the underlying genetic interactions of...